Theme: Covid-19 challenges for Technological and Clinical Advances in Cardiology

Euro Cardiology Congress 2020

Renowned Speakers

Euro Cardiology Congress 2020

Euro Cardiology Congress 2020 with a goal to empower healthcare providers welcomes all the professionals from Medical Healthcare, Cardiologists, Surgeons, Medicine Specialists, Professors, Medical Researchers, Nurses and Nurse Practitioners, Fellow Scholars, Industrial Professionals, Physicians and Student Delegates to our two-day event “2nd European Cardiology Congress” scheduled on August 21-22, 2020 

 Euro Cardiology Congress 2020 with the theme COVID-19 challenges for Technological and Clinical Advances in Cardiology will be featuring the world class keynote talk, speakers presenting clinical studies, oral and poster presentation with interactive networking session and workshops.

The main objective of Conference is to provide a platform for all the medical professionals including students to discuss and learn the new innovations on cardiology research, clinical updates and new discoveries with the cardiology and industrial experts to advance the ongoing research. The conference will highlight on Cardiac Surgery and Heart Failure, Cardio-Oncology and Resources, Congenital Heart Disease and Pediatric Cardiology, Diabetes and Cardiometabolic Disease, Advanced Lipid Testing, Geriatric Cardiology, Cardiomyopathies, Acute, chronic Heart Failure and Heart Transplant, Interventions and Coronary Artery Disease, Structural Heart Disease, Pulmonary Hypertension, Peripheral Vascular, Noninvasive Imaging, prevention, Sports and Exercise Cardiology, clinical updates, case reports.

Euro Cardiology Congress pact with an assembly course of 1000+ Global Events, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe and Asia and circulates 700+ Open Access journals which contains more than 30000 unique personalities, reputed specialists as article board people.

Why to Attend?

Euro Cardiology Congress 2020 is among the World's leading Scientific Conference to bring together worldwide distinguished healthcare experts in the field of cardiology, researchers, public health professionals, professors, academic scientists, industry researchers, scholars to exchange their ideas. You can take the opportunities of lectures from industry leaders, session on hot topics, interaction with company’s representatives, Meeting delegates and interaction over lunch and coffee breaks. The objective of this meeting is to stimulate new ideas for treatment and analyze the current market for the future direction of cardiovascular drugs, devices, and diagnostics, with a greater prominence on newer products that will be beneficial across the spectrum of Cardiology. We expect to welcome healthcare professionals from over 100 countries. We also have global faculty who are leading experts in their fields. Gain valuable awareness from these prominent professionals from skilled institutions.

Conference Opportunities

For Researchers and Faculty Members:

Speaker Presentations

Poster Display

Symposium hosting (4-5-member team)

Workshop organizing

For Universities, Associations & Societies:

Association Partnering

Collaboration proposals

Academic Partnering

Group Participation

For Students and Research Scholars:

Poster Competition (Winner will get Best Poster Award)

Young Researcher Forum (YRF Award to the best presenter)

Student Attendee

Group registrations

For Business Delegates:

Speaker Presentations

Symposium hosting

Book Launch event

Networking opportunities

Audience participation

For Product Manufacturers:

Exhibitor and Vendor booths

Sponsorships opportunities

Product launch

Workshop organizing

Scientific Partnering

Marketing and Networking with client


Cardiovascular diseases (CVDs) comprise disorders and conditions related to circulatory system which include heart and vascular system. The global cardiovascular drugs market is anticipated to reach the value of approximately US$ 91.0 Bn by 2025. Drug classes used to treat cardiovascular indications such as hyperlipidemia, hypertension are likely to fuel expansion of the global cardiovascular drugs market from 2017 to 2025.

Cardiovascular diseases are one of the leading causes of death worldwide. According to American Heart Association, it is estimated that cardiovascular disease is likely to increase to 45% by 2035. Sedentary lifestyle, changing dietary habits and surge in associated risk factors are likely to increase the number of patients with cardiovascular diseases. According to the Centers for Disease Control and Prevention (CDC) of the U.S., high blood pressure, high cholesterol, and smoking are key risk factors for heart disease. About half of the population of the U.S. (47%) have at least one of these three risk factors. To treat the diseases, key players are investing in to develop new drugs with better efficacy and less side effects.

The global cardiac biomarker diagnostic test kits market is expected to be worth US$ 2,540.8 Mn in 2028, and is projected to increase at a CAGR of 5.1% through 2028. North America is expected to be a dominant market, which accounted for US$ 522.5 Mn in 2017, and is expected to grow at a CAGR of 4.3%. North America has been the dominant regional market for heart diagnostics with a share of approximately 47% of the overall heart diagnostics market in terms of revenue in 2016, followed by Europe which accounted for around 38% share in the market and then by Asia accounting for 15% share.

Scope and Importance: -
A prospective survey of patients with valvular heart disease (VHD):
Coronary angiography was used in 85.2% of patients before intervention.
The Euro Heart Survey (EHS) programme has been initiated order to provide quantitative information on cardiovascular disease.
To prevent the incidence of cardiovascular (CV) disease, by implementing strategies to reduce the burden of CV risk factors and incidence of CV disease and
develop appropriate models for healthy CV lifestyle.

The global cardiovascular therapeutics market continues to see rapid innovation with new drugs and devices entering the market. According to our cardiovascular market research experts, diabetes is one of the major factors leading to the current cardiovascular disease epidemic. The growing prevalence of chronic diseases such as diabetes is the major factor leading to the growth of the heart failure market. Due to the potential breakthrough of newly approved drugs entering the market, heart failure market size is expected to grow in the coming years.

Cardiovascular Drugs Market

Major players in the global Cardiovascular drugs market include Merck & Co, Sanofi S.A, Pfizer Inc, Bristol-Myers Squibb Company, Novartis AG. The cardiovascular drugs market expected to reach a value of nearly $86.67 billion by 2022, significantly growing at a CAGR of 1.2% during the forecast period. The growth in the Cardiovascular drugs market is due to increase in aging population, increase in the prevalence of cardiovascular diseases and availability of more generic drugs that reduce the cost of treatment. Among the drugs used to treat cardiovascular diseases, the heart failure drugs market is one in particular expected to witness strong growth through 2022 due to the growing prevalence of chronic diseases such as diabetes. The global hypertension drugs market will post an impressive market value of  USD 32 billion by the end of 2020. The prevalence of hypertension is high among the older population with close to 70% of the patients with high BP above the age of 60.

Cardiovascular Ultrasound Devices Market Size and Growth Opportunities:

The ultrasound market is projected to reach USD 8.4 billion by 2023 from USD 6.3 billion in 2018, at a CAGR of 5.9% during the forecast period. Factors such as the increasing prevalence of target diseases, rising patient preference for minimally invasive procedures, technological advancements, increasing number of diagnostic centers & hospitals, and growing public and private investments, funding, and grants are driving the growth of the market during the forecast period. Cardiac Ultrasound System are the devices that are used in taking out live images or pictures of the heart. The clear images are used in early detection of cardiovascular diseases. There are several types of procedures relating to Cardiac ultrasound that includes transthoracic echocardiograph, 3D echocardiograph, electrocardiograph etc. Key players in the Cardiac Ultrasound Market : Canon Medical Systems Corporation; Koninklijke Philips N.V.; Hitachi; Fujifilm Medical Systems; GE Healthcare, Inc.; Siemens Healthcare; Kalamed Medical Systems; Chison Medical IMaging Co. Ltd.; Samsung Medison and Mindray Medical

The global medicine market includes interventional, internal organ devices. The worldwide interventional medicine devices market has been expected to understand $25.16 billion by 2020. On the opposite hand, the Asia Pacific market is anticipated to travel on top of $6.4 billion by 2022.

The global cardiovascular device industry is growing rapidly and exhibits signs that it will continue to evolve and expand.


To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date August 21-22, 2020
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Closed Day 1 Day 2
Poster Opportunity Closed Click Here to View